Bloodstream infections among human immunodeficiency virus-infected adult patients: epidemiology and risk factors for mortality

  • M. Ortega
  • M. Almela
  • A. Soriano
  • F. Marco
  • J. A. Martínez
  • A. Muñoz
  • G. Peñarroja
  • J. Mensa
Article

Abstract

This study was undertaken to describe the epidemiology and sensitivity pattern of pathogens causing community-acquired (CA) and nosocomial (N) bloodstream infection (BSI) in adult HIV-infected patients and to establish risk factors for mortality. The type of study was a retrospective analysis of BSI episodes prospectively collected through a blood culture surveillance program from January 1991 to December 2006. We used non-conditional logistic regression methods with death as a dependent variable. One thousand and seventy-seven episodes of BSI (6%) occurred in HIV-infected patients out of 16,946 episodes during the period of study. CA and N BSI were 634 (59%) and 443 (41%) respectively. S. pneumoniae and S. aureus were the most frequent pathogens (n = 279, 44%) in CA BSI. Coagulase-negative staphylococci and S. aureus were the most frequent micro-organisms isolated in N cases (n = 169, 38%). Cotrimoxazole resistance was common in CA and N BSI and was caused by gram-negative bacilli (50% and 61% respectively). However, resistance rates to ceftriaxone were low (3%). Crude mortality accounted for 140 cases (13%). The independent risk factors associated with mortality were: liver cirrhosis (OR: 2.90, p = 0.001), corticosteroids treatment (OR: 3.51, p < 0.001), neutropenia (OR: 2.21, p = 0.02), inappropriate empirical therapy (OR: 2.44, p = 0.006), and isolate of C. albicans (OR: 7.58, p = 0.010). BSI in adult HIV-infected patients was often caused by gram-positive pathogens in both CA and N settings. Inappropriate empirical therapy and the presence of other immunosuppressive factors were independent risk factors for mortality. Ceftriaxone could be used as the initial empiric therapy for HIV-infected patients with suspected CA BSI.

References

  1. 1.
    Eng R, Bishburg E, Smith S et al (1986) Bacteremia and fungemia in patients with acquired immune deficiency syndrome. Am J Clin Pathol 86:105–107PubMedGoogle Scholar
  2. 2.
    Witt DJ, Craven DE, McCabe WR (1987) Bacterial infection in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS related complex. Am J Med 82:900–906PubMedCrossRefGoogle Scholar
  3. 3.
    Krumholz HM, Sande MA, Lo B (1989) Community-acquired bacteremia in patients with acquired immunodeficiency syndrome: clinical presentation, bacteriology, and outcome. Am J Med 86:776–779PubMedCrossRefGoogle Scholar
  4. 4.
    Manfredi R, Cosiglioga P, Ricchi E et al (1993) Sepsis-bacteremia and other infections due to non-opportunistic bacterial pathogens in a consecutive series of 788 patients hospitalized for HIV infection. Clin Ter 143:279–290PubMedGoogle Scholar
  5. 5.
    Tumbarello M, Tacconelli E, Caponera S et al (1995) The impact of bacteremia on HIV infection. Nine years experience in a large Italian university hospital. J Infect 31:123–131PubMedCrossRefGoogle Scholar
  6. 6.
    Fichtenbaum CJ, Dunagan WC, Powderly WG (1995) Bacteremia in hospitalized patients infected with HIV: a case control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol 8:51–57PubMedGoogle Scholar
  7. 7.
    Ssali F, Kamya M, Wabwire-Mangen F et al (1998) A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol 19:484–489PubMedGoogle Scholar
  8. 8.
    Tumbarello M, Tacconelli E, Donati KG (1998) Nosocomial bloodstream infections in HIV-infected patient: attributable mortality and excess hospital stay. J Acquir Immune Defic Syndr Hum Retrovirol 19:490–496PubMedGoogle Scholar
  9. 9.
    Petrosillo N, Viale P, Nicastri E et al (2002) Nosocomial bloodstream infections among human immunodeficiency virus infected patients: incidence and risk factors. Clin Infect Dis 34:667–685CrossRefGoogle Scholar
  10. 10.
    Pedro-Botet ML, Mòdol JM, Valles X et al (2002) Changes in bloodstream infections in HIV-positive patients in a university hospital in Spain (1995–1997). Int J Infect Dis 6:17–22PubMedCrossRefGoogle Scholar
  11. 11.
    Murray P, Baron E, Pfaller M, Tenover F, Yolken R (eds) (1999) Manual of clinical microbiology, 7th edn. ASM Press, Washington, DCGoogle Scholar
  12. 12.
    Clinical and Laboratory Standard Intstitute (2006) Performance standards for antimicrobial susceptibility testing; Sixteenth Informational Supplement: Document M100-S16. CLSI, Wayne, PAGoogle Scholar
  13. 13.
    Annane D, Bellisant E, Cavaillon JM (2005) Septic shock. Lancet 365:63–78PubMedCrossRefGoogle Scholar
  14. 14.
    McGregor JC, Rich SE, Harris AD et al (2007) A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 45:329–337PubMedCrossRefGoogle Scholar
  15. 15.
    Martínez E, Milinkovic A, Buira E et al (2007) Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age from the same geographical area. HIV Med 8:251–258PubMedCrossRefGoogle Scholar
  16. 16.
    Anglaret X, Messou E, Ouassa T et al (2003) Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d’Ivoire. AIDS 17:575–584PubMedCrossRefGoogle Scholar
  17. 17.
    Javaloyas M, García-Somoza D, Gudiol F (2002) Epidemiology and prognosis of bacteremia: a 10 year study in a community hospital. Scand J Infect Dis 34:436–441PubMedCrossRefGoogle Scholar
  18. 18.
    Uzun O, Ascioglu S, Anaissie EJ et al (2001) Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 32:1713–1717PubMedCrossRefGoogle Scholar
  19. 19.
    Tumbarello M, Tacconelli E, Donati KG et al (2000) HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era. J Acquir Immune Defic Syndr 23:145–151PubMedGoogle Scholar
  20. 20.
    Meynard JL, Guiguet M, Fonquernie L et al (2003) Impact of highly active antiretroviral therapy on the occurrence of bacteraemia in HIV-infected patients and their epidemiologic characteristics. HIV Med 4:127–132PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • M. Ortega
    • 1
    • 4
  • M. Almela
    • 2
  • A. Soriano
    • 3
  • F. Marco
    • 2
  • J. A. Martínez
    • 3
  • A. Muñoz
    • 3
  • G. Peñarroja
    • 3
  • J. Mensa
    • 3
  1. 1.Emergency Department, Hospital Clínic, IDIBAPSUniversity of BarcelonaBarcelonaSpain
  2. 2.Microbiology Laboratory, Hospital Clínic, IDIBAPSUniversity of BarcelonaBarcelonaSpain
  3. 3.Department of Infectious Diseases, Hospital Clínic, IDIBAPSUniversity of BarcelonaBarcelonaSpain
  4. 4.Emergency DepartmentHospital ClínicBarcelonaSpain

Personalised recommendations